The clinical case for newborn sickle cell screening in the regions where the disease is most prevalent is overwhelming. The World Health Organization and the U.S. CDC both estimate that sub-Saharan Africa accounts for roughly three-quarters of the global sickle cell disease burden. Mortality in untreated children with HbSS in low-resource settings has historically exceeded 50% before age five. Early identification, hydroxyurea where available, malaria prophylaxis, and pneumococcal vaccination together change that mortality dramatically.
The screen has to happen first. For programs operating outside reference-laboratory infrastructure, that screen needs to be a rapid lateral-flow test that a community health worker can run in the place where the newborn is. Designing that product is, surprisingly, less about the chemistry than about everything around the chemistry.
What the lab assumes that the field cannot
A lateral-flow assay developed in a reference-lab environment carries assumptions: refrigerated storage, calibrated pipettes, controlled humidity, electric lighting, trained reading. Each assumption fails in some part of the deployment environment. The design challenge is to identify which failures matter most and engineer around them.
- Cold chain. Rapid sickle cell tests need to remain stable through tropical heat and humidity. Lyophilized reagents and stabilized membranes help. Cassette packaging that controls moisture matters more than most teams initially expect.
- Sample volume. A community health worker working with heel-stick newborn samples cannot reliably deliver 10 microliters with a precision pipette. The cassette has to tolerate volume variation, ideally with a pre-measured collection device.
- Buffer delivery. A separate buffer dropper bottle is one more item to lose, contaminate, or run out of. Pre-loaded cassettes or single-use buffer ampoules reduce field error substantially.
- Read interpretation. Faint lines, ambient lighting variation, and reader fatigue produce a known misread rate. A printed reference key or a phone-based interpretation aid can close most of that gap.
- Disposal. Biohazard disposal infrastructure is variable. The cassette materials and packaging need to support whatever the local protocol actually is.
What a postal-compliant collection device changes
One of the under-appreciated design constraints in field-deployable diagnostics is what happens between the patient and the test, particularly when sample collection and testing are not in the same place. A collection vessel that fits standard postal envelopes (in the United States, that means an internal thickness at or below roughly 0.22 inches) opens up a mail-in workflow that bypasses local collection-clinic infrastructure entirely.
Our team has spent significant engineering time on a collapsible micro-vessel that meets postal-thickness rules while delivering a calibrated sample volume and a smooth interior wall (no membrane-disrupting ridges, no pipette-trapping geometry). The application is broader than sickle cell, but the sickle cell screening case is among the clearest. A single integrated kit with collection device, cassette, buffer, and reference reading aid can be shipped, used in any clinic or even in a patient's home, and returned for confirmatory testing where appropriate.
The sample-collection step is the part of the workflow most teams under-engineer. It is also the part most likely to determine whether the result is usable.
The interpretation aid
Rapid sickle cell cassettes traditionally interpret as visible test lines indicating the presence or absence of HbA, HbS, and (in some products) HbC. The reading is straightforward when lines are bold. The misread rate climbs in heterozygous (HbAS) samples where the HbS line is dimmer than the HbA line, and in low-light settings.
A printed interpretation key, included in the kit and aligned with the read window, gives the reader an explicit visual reference. We have done substantial work on this approach, including in the patent literature, on the premise that the unit cost of an additional printed insert is trivial compared to the impact on misread rates. The same key can be designed to support phone-camera interpretation, which is the natural next step.
What program operators actually want
From the conversations we have had with screening-program operators across multiple countries, the recurring requests are not exotic. They are operational:
- A test that survives transport without refrigeration.
- A test that a non-laboratorian can run with one short training session.
- A test that produces a result the program can document, ideally with a captured image.
- A clear pathway for confirmatory testing of positives, with a sample-collection format that can be mailed.
- A unit cost that fits inside a Ministry-of-Health screening budget.
None of those is a chemistry request. They are all design and deployment requests. They are the ones that decide whether the test is used at all, in the places where the disease burden is highest.
The next stage
The technical components for a deployable rapid sickle cell screening workflow exist today: validated lateral-flow chemistry, postal-compliant sample collection, printed interpretation aids, smartphone-based image capture, and registry software that syncs when connectivity returns. The unsolved problem is integrating those components into a single kit, validating the integrated workflow at scale, and getting the resulting product priced for the screening programs that need it.
That is the work in front of the field. It is not a chemistry problem.